CN104181307A - Diagnostic method for assessing state of atopic dermatitis by CTACK/CCL27 - Google Patents
Diagnostic method for assessing state of atopic dermatitis by CTACK/CCL27 Download PDFInfo
- Publication number
- CN104181307A CN104181307A CN201410412665.3A CN201410412665A CN104181307A CN 104181307 A CN104181307 A CN 104181307A CN 201410412665 A CN201410412665 A CN 201410412665A CN 104181307 A CN104181307 A CN 104181307A
- Authority
- CN
- China
- Prior art keywords
- ctack
- ccl27
- atopic dermatitis
- state
- diagnostic method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a diagnostic method for assessing the state of atopic dermatitis by CTACK/CCL27. According to the method disclosed by the invention, by using the high correlation between the content of CTACK/CCL27 protein in the blood serum of a patient and an SCORAD scoring method used in general diagnosis, the content of the CTACK/CCL27 protein in the blood serum of the patient suffering from atopic dermatitis is assayed by using Elisa instead of judging the severity of the state of the patient suffering from atopic dermatitis by the SCORAD scoring method in the prior art. By using the method disclosed by the invention, the workload of doctors can be greatly reduced, the influence caused by subjective factors during diagnosis is lowered, the accuracy of diagnosis and dosage is improved, and thus, good news is brought for the patient.
Description
Technical field
The present invention relates to biology field, be specifically related to a kind of by the diagnostic method of CTACK/CCL27 assessment atopic dermatitis state of an illness.
Background technology
Atopic dermatitis is the class chronic dermatosis that the incidence of disease is very high, not difficult for the diagnosis of atopic dermatitis.Selection and the diagnostic method that standard adapts realize the effective treatment to atopic dermatitis, it diagnosed accurately with the most important standard treatment of reaching extensive common recognition of state of an illness assessment and is also announced, as long as can judge without difficulty.
For symptom and the order of severity of atopic dermatitis, although introduced SCORAD point system, assess skin and show symptom and development, based on the method seriousness can be divided into slightly, moderate and severe.Yet because appraisal procedure is too complicated, SCORAD is not widespread use in clinical.
The CTACK/CCL27 cDNA 112 amino acid whose amyloid protein precursors of encoding, wherein front 24 amino acid, as signal peptide, finally become 88 amino acid whose maturation proteins through shearing.CTACK/CCL27 is mainly produced by horn cell, and its acceptor is CCR10.CTACK/CCL27 can selectivity attract CLA+ T lymphocyte to impaired skin part.In atopic dermatitis patients serum, the level of CTACK/CCL27 is consistent with the evaluation result height of SCORAD point system.In crossing the transgenic mice express CTACK/CCL27, show higher Th2 susceptibility, and show obvious atopic dermatitis symptom.
Therefore, can there is the method for CTACK/CCL27 protein level in a kind of quantitative detection serum may replace SCORAD point system to judge symptom and the order of severity of atopic dermatitis.
Summary of the invention
The object of the invention is to create a kind of method of quantification, the assessment of atopic dermatitis severity of symptom is simplified, alleviate doctor's burden, improve the accuracy detecting simultaneously.
Above-mentioned purpose of the present invention is achieved by the following technical programs:
By Elisa antibody sandwich method, detect in patients serum, according to the order of severity of the concentration judgement patient-specific dermatitis state of an illness of its CTACK/CCL27 albumen, and then give applicable medication.
Compared with prior art, the present invention has following beneficial effect:
The present invention is converted into the simple and easy objective detection method of a kind of quantification by the complicated state of an illness detection method loaded down with trivial details and that subjectivity is heavier of atopic dermatitis, has alleviated doctor's burden, has also increased the accuracy detecting.
Accompanying drawing explanation
Fig. 1 is CTACK/CCL27 typical curve, and horizontal ordinate is CTACK/CCL27 protein content, and ordinate is absorbance;
Fig. 2 is after small sample detects, the CTACK/CCL27 protein content in each case serum and SCORAD appraisal result, and wherein horizontal ordinate is SCORAD appraisal result, ordinate is CTACK/CCL27 protein content.
Embodiment
Below in conjunction with embodiment, further explain the present invention, but embodiment does not limit in any form to the present invention.
1. by the coated solid phase carrier of CTACK/CCL27 antibody.Hatch certain hour, make to form insolubilized antibody, unconjugated antibody and impurity are removed in washing.
2. add sample to be checked, hatch, the antigen in sample is fully reacted with the antibody on solid phase carrier, form solid phase antigen antibody complex.Washing is removed other not in conjunction with material.
3. the anti-CTACK/CCL27 antibody of enzyme-added mark, hatches, and makes to form insolubilized antibody determined antigen enzyme labelled antibody sandwich complex.Not desmoenzyme labeling antibody is removed in washing.
4. add substrate colour developing.Substrate for enzymatic activity in solid phase produces coloured product, by the amount of antibody in colorimetric mark basis.
5. the standard items that obtained and the luminous value of sample are as ordinate, and CTACK/CCL27 protein concentration is made typical curve as horizontal ordinate, and the concentration of each sample can be read from typical curve.
Typical curve is as follows, and the CTACK/CCL27 standard items of getting concentration and be 0.1,0.2,0.5,1.0,1.5,2.0,2.5,3ng/ml obtain typical curve as shown in Figure 1.
6. atopic dermatitis small sample detects as shown in Figure 2, and in serum, the content of CTACK/CCL27 in serum is consistent with SCORAD appraisal result height.
Claims (1)
1. a diagnostic method of assessing the atopic dermatitis state of an illness, it is characterized in that by have can check mark CTACK/CCL27 antibody, CTACK/CCL27 protein combination during specific and blood in human body in is clear, determine the content of CTACK/CCL27 albumen in serum, in serum, the number of CTACK/CCL27 protein content has reflected the order of severity of atopic dermatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410412665.3A CN104181307A (en) | 2014-08-21 | 2014-08-21 | Diagnostic method for assessing state of atopic dermatitis by CTACK/CCL27 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410412665.3A CN104181307A (en) | 2014-08-21 | 2014-08-21 | Diagnostic method for assessing state of atopic dermatitis by CTACK/CCL27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104181307A true CN104181307A (en) | 2014-12-03 |
Family
ID=51962528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410412665.3A Pending CN104181307A (en) | 2014-08-21 | 2014-08-21 | Diagnostic method for assessing state of atopic dermatitis by CTACK/CCL27 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104181307A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108330184A (en) * | 2017-01-19 | 2018-07-27 | 深圳北京大学香港科技大学医学中心 | A kind of method of quick screening atopic dermatitis sample |
| RU2692955C1 (en) * | 2018-06-25 | 2019-06-28 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Method for assessing the severity of atopic dermatitis in children by optical coherence tomography |
-
2014
- 2014-08-21 CN CN201410412665.3A patent/CN104181307A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108330184A (en) * | 2017-01-19 | 2018-07-27 | 深圳北京大学香港科技大学医学中心 | A kind of method of quick screening atopic dermatitis sample |
| RU2692955C1 (en) * | 2018-06-25 | 2019-06-28 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Method for assessing the severity of atopic dermatitis in children by optical coherence tomography |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ali et al. | Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis | |
| Gunderson et al. | History of gestational diabetes mellitus and future risk of atherosclerosis in mid‐life: the coronary artery risk development in young adults study | |
| Stasi et al. | Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness | |
| Ky et al. | High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure | |
| González-García et al. | Short-term prognostic value of serum neuron specific enolase and S100B in acute stroke patients | |
| JP6927212B2 (en) | Evaluation method for mild cognitive impairment or Alzheimer's disease | |
| JP2020190565A (en) | Biomarker and method for detecting seizure and epilepsy | |
| US10509044B2 (en) | Methods for assessing differential risk for developing heart failure | |
| CN105917232B (en) | Method for selective determination of placental growth factor 2 | |
| EP3030901B1 (en) | Methods and kits for predicting the risk of having a cardiovascular event | |
| WO2005080982A1 (en) | Method of discriminating type a and type b acute aortic dissections from acute myocardial infarction and discrimination kit | |
| Kim et al. | Serum S100B protein is associated with depressive symptoms in patients with end-stage renal disease | |
| CN104181291A (en) | Diagnostic method for assessing state of atopic dermatitis by TARC/CCL17 | |
| CN104181307A (en) | Diagnostic method for assessing state of atopic dermatitis by CTACK/CCL27 | |
| CN116547536A (en) | GDF-15 for predicting disease severity in patients with COVID-19 | |
| RU2653682C1 (en) | Method for rapid diagnosis of the form of disorder of schizophrenic spectrum | |
| JP2010507093A (en) | Biomarker | |
| Cui et al. | Relationship between circulating concentration of Ang II, ADM and ADT and left ventricular hypertrophy in hypertension | |
| US20160161499A1 (en) | Sensitive diagnostic assay for inclusion body mysitis | |
| JP2017516119A (en) | Early placental insulin-like peptide (pro-EPIL) | |
| Oliveira et al. | Arterial hypertension and metabolic profile in patients with polycystic ovary syndrome | |
| JP7311857B2 (en) | Method and reagent for detecting neuropathic pain by autotaxin measurement | |
| KR20140023260A (en) | METHOD FOR TESTING FOR CEREBRAL INFARCTION VIA CARTILAGE ACIDIC PROTEIN l | |
| WO2020140425A1 (en) | Application of group of serum differential protein combinations in preparing reagents for detecting autism | |
| Suriyaprom et al. | Homocysteine but not serum amyloid A, vitamin A and E related to increased risk of metabolic syndrome in post-menopausal Thai women |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141203 |